These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 10091625)

  • 1. Effect of muscle activity immediately after botulinum toxin injection for writer's cramp.
    Chen R; Karp BI; Goldstein SR; Bara-Jimenez W; Yaseen Z; Hallett M
    Mov Disord; 1999 Mar; 14(2):307-12. PubMed ID: 10091625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the guidance method affect the doses of botulinum toxin in writer's cramp?
    Kreisler A; Watel K; Defebvre L; Mortain L; Duhamel A
    Rev Neurol (Paris); 2024 Jun; 180(6):548-558. PubMed ID: 38336523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incobotulinum Toxin-A in Professional Musicians with Focal Task-Specific Dystonia: A Double Blind, Placebo Controlled, Cross-Over Study.
    Frucht SJ; George MC; Pantelyat A; Altenmueller E; Nmashie A; Jiao JM; Chen M; Feng D; Shin S; Kaku MC; Simpson D
    Tremor Other Hyperkinet Mov (N Y); 2024; 14():32. PubMed ID: 38948014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pronator teres muscle botulinum neurotoxin type-A injection on proximal median nerve entrapment.
    Özdemir A; Güleç A; Yurteri A; Odabaşı E; Acar MA
    Hand Surg Rehabil; 2024 Feb; 43(1):101604. PubMed ID: 37797787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive impairment assessment through handwriting (COGITAT) score: a novel tool that predicts cognitive state from handwriting for forensic and clinical applications.
    Balestrino M; Brugnolo A; Girtler N; Pardini M; Rizzetto C; Alì PA; Cocito L; Schiavetti I
    Front Psychol; 2024; 15():1275315. PubMed ID: 38605845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive effect of self-exercise following Botulinum toxin injection on the permanence of the recovery among the patients with HFS and BFS: A clinical trial.
    Sari ÜS; Eroglu M; Büyükşerbetçi G; Tokucoglu F; Sahin N
    Medicine (Baltimore); 2024 Jun; 103(24):e38215. PubMed ID: 38875371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denervation Dynamics After Intramuscular BNT Injection in Patients With Focal Spasticity Monitored by MRI and Dynamometry-a Blinded Randomized Controlled Pilot Study.
    Macher S; Unger E; Zalaudek M; Weber M; Kranz G; Kranz G; Kasprian G; Sycha T
    Front Neurol; 2021; 12():719030. PubMed ID: 34867709
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for central antispastic effect of botulinum toxin type A.
    Matak I
    Br J Pharmacol; 2020 Jan; 177(1):65-76. PubMed ID: 31444910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of botulinum neurotoxin: Unexpected consequences.
    Hallett M
    Toxicon; 2018 Jun; 147():73-76. PubMed ID: 28803760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them.
    Hallett M
    Toxicon; 2015 Dec; 107(Pt A):64-7. PubMed ID: 26220801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responsiveness to botulinum toxin type A in muscles of complex regional pain patients with tonic dystonia.
    Schilder JC; van Dijk JG; Dressler D; Koelman JH; Marinus J; van Hilten JJ
    J Neural Transm (Vienna); 2014 Jul; 121(7):761-7. PubMed ID: 24532257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of focal dystonia.
    Batla A; Stamelou M; Bhatia KP
    Curr Treat Options Neurol; 2012 Jun; 14(3):213-29. PubMed ID: 22415705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for the use of botulinum toxin in movement disorders and spasticity.
    Jabeen A; Kandadai RM; Kannikannan MA; Borgohain R
    Ann Indian Acad Neurol; 2011 Jul; 14(Suppl 1):S31-4. PubMed ID: 21847327
    [No Abstract]   [Full Text] [Related]  

  • 14. [Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].
    Wissel J; auf dem Brinke M; Hecht M; Herrmann C; Huber M; Mehnert S; Reuter I; Schramm A; Stenner A; van der Ven C; Winterholler M; Kupsch A
    Nervenarzt; 2011 Apr; 82(4):481-95. PubMed ID: 21079908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal characteristics of botulinum neurotoxin therapy.
    Lebeda FJ; Cer RZ; Stephens RM; Mudunuri U
    Expert Rev Neurother; 2010 Jan; 10(1):93-103. PubMed ID: 20021324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vocal exercise versus voice rest following botulinum toxin injections: a randomized crossover trial.
    Paniello RC; Edgar JD; Perlmutter JS
    Ann Otol Rhinol Laryngol; 2009 Nov; 118(11):759-63. PubMed ID: 19999359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of focal dystonias with botulinum neurotoxin.
    Hallett M; Benecke R; Blitzer A; Comella CL
    Toxicon; 2009 Oct; 54(5):628-33. PubMed ID: 19103214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.
    Schulte-Mattler WJ
    CNS Drugs; 2008; 22(9):725-38. PubMed ID: 18698873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Simpson DM; Blitzer A; Brashear A; Comella C; Dubinsky R; Hallett M; Jankovic J; Karp B; Ludlow CL; Miyasaki JM; Naumann M; So Y;
    Neurology; 2008 May; 70(19):1699-706. PubMed ID: 18458230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for the effectiveness of botulinum toxin for writer's cramp.
    Dashtipour K; Pender RA
    J Neural Transm (Vienna); 2008; 115(4):653-6. PubMed ID: 18322638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.